Antilipemic Agents Clinical Trials

All Categories Medications / Interventions » Aa » Antilipemic Agents

Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

Condition: HIV Dementia
Interventions: Drug: Lipitor; Drug: placebo
Sponsors: University of Pennsylvania; University of Pennsylvania
Not yet recruiting - verified May 2012
Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy

Condition: Coronary Artery Disease
Interventions: Drug: standard of care lipid therapy (Zocor, Lipitor, Crestor); Drug: Aggressive lipid therapy with Crestor 40mg
Sponsors: Mount Sinai School of Medicine; Annapoorna Kini
Recruiting - verified March 2012
Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients

Condition: Second or Third Degree Burns
Interventions: Drug: Fenofibrate; Drug: placebo
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; Shriners Hospitals for Children
Recruiting - verified May 2012
Study of Metformin With Simvastatin for Men With Prostate Carcinoma

Condition: Prostate Carcinoma
Interventions: Drug: Metformin; Drug: Simvastatin
Sponsors: Baylor College of Medicine; Nicholas Mitsiades
Recruiting - verified March 2012
Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy

Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: atorvastatin calcium; Drug: placebo
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified March 2012
Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

Condition: Saphenous Vein Graft Disease
Interventions: Drug: Atorvastatin 80 mg daily; Drug: Atorvastatin 10 mg daily
Sponsors: Boca Raton Regional Hospital; Boca Raton Regional Hospital; Pfizer
Recruiting - verified March 2012
Atorvastatin Calcium-Treated Donor Peripheral Blood Stem Cell Transplant in Preventing Severe Graft-Versus-Host Disease in Patients With Hematological Malignancies

Conditions: Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Previously Treated Myelodysplastic Syndromes; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: atorvastatin calcium; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Donor Atorvastatin Calcium in Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Blood Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Low Risk Metastatic Gestational Trophoblastic Tumor; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Gestational Trophoblastic Tumor; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: atorvastatin calcium; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)

Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Neoplasms
Interventions: Drug: Rosuvastatin; Drug: Placebo
Sponsors: University of Vermont; University of Vermont
Recruiting - verified March 2012
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Drug: dalcetrapib; Drug: Placebo; Other: Background care
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Clinical Trial of Simvastatin to Treat Generalized Vitiligo

Condition: Vitiligo
Interventions: Drug: Simvastatin; Drug: Placebo
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified April 2012
Triclosan, Triclocarban, and the Microbiota

Condition: Triclosan Effects on Microbial Flora.
Intervention: Other: triclosan/triclocarban-containing personal care products
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.

Condition: Cardiovascular Diseases
Interventions: Drug: AMR101; Drug: Placebo
Sponsors: Amarin Pharma Inc.; Amarin Pharma Inc.
Recruiting - verified March 2012
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Myelodysplastic Syndrome
Interventions: Drug: atorvastatin; Drug: Tacrolimus; Drug: methotrexate
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified January 2012
Drug-Drug Interaction Study With Pravastatin and Cyclosporine

Condition: Healthy
Interventions: Drug: Pravastatin alone; Drug: Pravastatin and Cyclosporine
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institute of General Medical Sciences (NIGMS)
Not yet recruiting - verified December 2011
Effects of Acipimox on Mitochondrial Function in Obesity

Conditions: Abdominal Obesity; Insulin Resistance; Hypertriglyceridemia
Interventions: Drug: Acipimox; Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; American Diabetes Association
Not yet recruiting - verified January 2012
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

Conditions: Dyslipidemia; Healthy Volunteers
Intervention: Drug: TAP311
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Atorvastatin; Other: Placebo to sitagliptin; Other: Placebo to atorvastatin; Drug: Metformin; Drug: Glimepiride; Drug: Placebo to glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2012
A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease

Condition: Chronic Kidney Disease
Interventions: Other: K2CG chewing gum (20mg chitosan); Other: K2CG chewing gum (60mg chitosan); Other: No intervention
Sponsors: Denver Nephrologists, P.C.; Denver Nephrologists, P.C.; CM&D Pharma Limited
Recruiting - verified November 2011
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

Condition: HIV-1 Infection
Interventions: Drug: Pravastatin sodium; Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate; Drug: Pravastatin sodium
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012
Pre-Prostatectomy Lovastatin on Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Lovastatin
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012
Drug Interaction Study of Clopidogrel and Rosuvastatin

Condition: Healthy
Interventions: Drug: Rosuvastatin; Drug: Clopidogrel
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012
Endothelial Facilitation in Alzheimer's Disease

Condition: Alzheimer's Disease
Intervention: Drug: Simvastatin + L-Arginine + Tetrahydrobiopterin
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified May 2012
SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation

Condition: Smith-Lemli-Opitz Syndrome
Interventions: Drug: Simvastatin; Dietary Supplement: Lactose
Sponsors: Oregon Health and Science University; Oregon Health and Science University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2012
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities

Condition: Kawasaki Disease
Intervention: Drug: Atorvastatin
Sponsors: University of California, San Diego; University of California, San Diego
Not yet recruiting - verified September 2011
Stanford's Outcomes Research in Kids

Condition: Bacterial, Viral and Other Infectious Agents
Intervention: Other: Removal of triclosan-containing cleaning products from household.
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011
Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection

Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012
Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer

Condition: Liver Cancer
Intervention: Drug: Fluoromethylcholine (FCH) PET/CT Imaging
Sponsors: Queen's Medical Centre; Queen's Medical Centre; Hawaii Medical Center; University of Hawaii
Recruiting - verified April 2012
Effects of Gastric pH on the Pharmacokinetics of Dasatinib

Condition: Healthy
Interventions: Drug: Dasatinib; Drug: Dasatinib plus Rabeprazole; Drug: Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Sponsors: University of California, San Francisco; University of California, San Francisco; Genentech
Recruiting - verified November 2011
Fluvastatin, Simvastatin to Improve Interferon Sensitivity

Condition: Chronic Hepatitis C
Intervention: Drug: statin
Sponsors: Bader, Ted, M.D.; Bader, Ted, M.D.
Not yet recruiting - verified June 2011
To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects

Condition: Inflammation
Intervention: Drug: Vytorin
Sponsors: Kaleida Health; Kaleida Health
Recruiting - verified March 2011
Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Drug: Acipimox; Drug: Placebo
Sponsors: University of Colorado, Denver; University of Colorado, Denver; Department of Veterans Affairs; Pfizer
Recruiting - verified April 2012
Statin Discontinuation in Advanced Illness

Conditions: Palliative Medicine; Cardiovascular Disease
Intervention: Other: discontinue statins
Sponsors: Palliative Care Research Cooperative Group; Palliative Care Research Cooperative Group; National Institute of Nursing Research (NINR)
Recruiting - verified March 2012
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: cyclosporine; Drug: pravastatin sodium; Drug: mitoxantrone hydrochloride; Drug: etoposide; Procedure: bone marrow aspiration
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Conditions: Drug Interactions; BRAF; Cancer
Interventions: Drug: Warfarin; Drug: Ketoconazole; Drug: Gemfibrozil; Drug: GSK2118436 150mg; Drug: GSK2118436 75mg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

Condition: Myeloma
Intervention: Drug: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
Sponsors: James Graham Brown Cancer Center; Geoffry Herzig, MD
Recruiting - verified April 2012
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified October 2011
A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume

Conditions: Type 1 Diabetes Mellitus; Retinopathy; Diabetic Nephropathy
Interventions: Drug: Fenofibrate; Drug: Inert lactose placebo
Sponsors: University of Sydney; University of Sydney; Abbott; University of Melbourne; St Vincents Hospital, Melbourne; Melbourne Health; Royal Prince Alfred Hospital, Sydney, Australia
Not yet recruiting - verified March 2011
Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: rosuvastatin
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified February 2012
Insulin Resistance in Non-alcoholic Fatty Liver Disease

Condition: Fatty Liver
Interventions: Drug: fenofibrate; Drug: pioglitazone; Drug: placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012
Modulation of Monocyte Activation by Atorvastatin in HIV Infection

Condition: HIV Dementia
Intervention: Drug: Atorvastatin
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Colesevelam Pediatric Type 2 Diabetes Mellitus Study

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol for oral suspension placebo proxy; Drug: Welchol for oral suspension
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified April 2012
Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

Conditions: Acute Coronary Syndrome; Angioplasty, Transluminal, Percutaneous Coronary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Blood Platelets
Interventions: Drug: rosuvastatin; Drug: placebo
Sponsors: University of Kentucky; University of Kentucky
Recruiting - verified March 2012
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Condition: HIV-1 Infection
Interventions: Drug: atorvastatin; Drug: atorvastatin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Pfizer
Recruiting - verified September 2011
Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children

Conditions: Obesity; Short Stature
Interventions: Drug: Niacin; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012
Statins in Children With Type 1 Diabetes and Hypercholesterolemia

Conditions: Diabetes Mellitus, Insulin-Dependent; Hypercholesterolemia
Interventions: Drug: Atorvastatin; Drug: Atorvastatin Placebo
Sponsors: Nemours Children's Clinic; Nemours Children's Clinic; Pfizer; Medtronic; Quest Diagnostics
Recruiting - verified May 2012
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (Protocol MK-0524A-133 AM1)

Conditions: Primary Hypercholesterolemia; Mixed Dyslipidemia
Interventions: Drug: Extended-release niacin/laropiprant (ERN/LRPT); Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified April 2012
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis

Conditions: Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis; Intermediate Saphenous Vein Graft Lesions
Intervention: Drug: extended-release niacin (Niaspan)
Sponsors: North Texas Veterans Healthcare System; North Texas Veterans Healthcare System; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2011
Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

Conditions: HIV Infections; Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks; Drug: Placebo
Sponsors: University Hospitals of Cleveland; University Hospitals of Cleveland; National Institutes of Health (NIH); AstraZeneca
Recruiting - verified January 2012
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

Conditions: Atherosclerosis; Hypercholesterolemia
Interventions: Drug: LDL. Cholesterol (Statin Drugs); Drug: HMG-CoA Reductase Inhibitors
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified July 2011
Statin/Vitamin D & Migraine Study

Condition: Migraine
Interventions: Drug: Simvastatin; Dietary Supplement: Vitamin D; Other: Placebo
Sponsors: Beth Israel Deaconess Medical Center; Rami Burstein
Recruiting - verified January 2012
Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol

Condition: Healthy Volunteers
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid

Conditions: Dialysis; Cardiovascular Disease; Atherosclerosis; Inflammation
Intervention: Drug: Extended Release Nicotinic Acid (Niaspan)
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital
Recruiting - verified June 2011
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)

Condition: Hypercholesterolemia
Interventions: Drug: ezetimibe (+) atorvastatin; Drug: Comparator: ezetimibe (+) atorvastatin; Drug: Comparator: atorvastatin, switching to ezetimibe (+) atorvastatin; Drug: Comparator: atorvastatin; Drug: Comparator: rosuvastatin, switching to ezetimibe (+) atorvastatin; Drug: Comparator: rosuvastatin
Sponsors: Merck; Merck
Recruiting - verified May 2012
Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure

Conditions: Fetal Alcohol Spectrum Disorders; Fetal Alcohol Syndrome; Partial Fetal Alcohol Syndrome; Alcohol Related Neurodevelopmental Disorder; Prenatal Alcohol Exposure
Interventions: Drug: Choline bitartrate; Dietary Supplement: Placebo for choline bitartrate
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012
Effects of Simvastatin on Biomarkers

Condition: Alzheimer's Disease
Interventions: Drug: Simvastatin; Drug: Placebo
Sponsors: University of Washington; University of Washington; Seattle Institute for Biomedical and Clinical Research; VA Puget Sound Health Care System
Recruiting - verified March 2012
CoEnzyme Q10 in Statin Myopathy

Condition: Statin Myopathy
Interventions: Drug: CoEnzyme Q10; Drug: Placebo
Sponsors: Hartford Hospital; Hartford Hospital
Recruiting - verified January 2012
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorders; Schizophreniform Disorders
Interventions: Drug: Pravastatin; Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Stanley Medical Research Institute; North Suffolk Mental Health Association
Recruiting - verified April 2012
Simvastatin Therapy for Moderate and Severe COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: simvastatin; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Intervention: Drug: C11-Choline
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified September 2010
Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer

Conditions: Cardiovascular Complications; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: rosuvastatin; Other: placebo; Other: survey administration; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
To Investigate the Role of Upstream High Dose Statin in STEMI

Condition: Acute Myocardial Infarction
Interventions: Drug: Atorvastatin calcium; Drug: Inactive Placebo
Sponsors: The Western Pennsylvania Hospital; The Western Pennsylvania Hospital; West Penn Allegheny Health System
Recruiting - verified August 2011
Metabolic Features of Post-Myopathy Patients Associated With Statin Treatment

Condition: Myopathy (Statin Associated)
Intervention:
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified October 2011
Chitosan Dressings to Facilitate Safe Effective Debridement of Chronic Wounds & Minimize Wound Bacterial Re-colonization

Condition: Wound Debridement
Interventions: Device: HemCon Dressings and HemCon ChitoGauze; chitosan-based.; Device: HemCon Dressings and HemCon ChitoGauze; chitosan-based.; Device: Gauze and saline dressings.; Device: Gauze and saline dressings.
Sponsors: HemCon Medical Technologies, Inc; HemCon Medical Technologies, Inc
Recruiting - verified June 2011
Predictors of Response to Fenofibrate

Conditions: Hypertriglyceridemia; Insulin Resistance
Intervention: Drug: Fenofibrate
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Tufts University; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified March 2012
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Intensive Lipid-Lowering Therapy for Patients With Acute Coronary Syndrome

Condition: Acute Coronary Syndrome
Interventions: Procedure: Percutaneous coronary intervention; Procedure: Intravascular ultrasound with virtual histology; Drug: Atorvastatin; Device: LDL-apheresis
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012
Benefit of CoQ-10 in Patients on Statins

Conditions: Pain; Soreness; Weakness; Fatigue
Interventions: Dietary Supplement: Co-enzyme Q-10; Dietary Supplement: Placebo
Sponsors: Stony Brook University; Stony Brook University
Recruiting - verified August 2011
Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins

Condition: Hyperglycemia
Interventions: Drug: 5% dextrose; Drug: vitamin C; Drug: Simvastatin; Drug: L-NMMA
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012
Simvastatin for the Treatment of Chronic Hepatitis B

Condition: Hepatitis B
Interventions: Drug: Simvastatin; Drug: Tenofovir; Drug: Entecavir
Sponsors: Bader, Ted, M.D.; Bader, Ted, M.D.
Recruiting - verified June 2011
Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

Condition: Coronary Artery Disease
Intervention: Drug: Atorvastatin
Sponsors: Indiana University; Indiana University School of Medicine; National Center for Research Resources (NCRR)
Recruiting - verified November 2010
Statins for Acutely Injured Lungs From Sepsis

Condition: Sepsis Induced ALI
Interventions: Drug: Rosuvastatin; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2012
Statin Therapy to Improve Atherosclerosis in HIV Patients

Conditions: Cardiovascular Disease; HIV; Atherosclerosis; Inflammation; Statins, HMG-CoA; HIV Infections
Interventions: Drug: atorvastatin; Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Citicoline Treatment of Methamphetamine Dependence

Condition: Methamphetamine Dependence
Interventions: Drug: Citicoline; Drug: Placebo
Sponsors: University of Utah; Perry Renshaw; National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2012
Effect of Rosuvastatin Response in Healthy Subjects: Potential Mechanisms of Anti-inflammatory Effects

Condition: Healthy
Intervention:
Sponsors: University of Nebraska; University of Nebraska
Recruiting - verified August 2011
The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans

Condition: Hypertension
Interventions: Drug: fenofibrate; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH)
Recruiting - verified July 2011
Niacin and Endothelial Function in Early CKD

Condition: Chronic Kidney Disease
Interventions: Drug: Niacin; Drug: Active Placebo
Sponsors: Tufts Medical Center; Tufts Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

Condition: Neurofibromatosis Type 1
Interventions: Drug: Lovastatin ™; Device: placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Children's Hospital Boston; Children's Hospital Philadelphia; Children's Research Institute; Children's Hospital Medical Center, Cincinnati; National Cancer Institute (NCI); University of Chicago; University of Utah; Washington University School of Medicine; The Children's Hospital at Westmead
Recruiting - verified July 2011
Atorvastatin Three Year Pediatric Study

Condition: Familial Hypercholesterolemia
Intervention: Drug: atorvastatin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Novel Therapies for Resistant FSGS (FONT II): Phase II Clinical Trial

Condition: Focal Segmental Glomerulosclerosis
Interventions: Drug: Adalimumab; Drug: Lisinopril, losartan, and atorvastatin; Drug: galactose
Sponsors: New York University School of Medicine; New York University School of Medicine; University of Michigan; The Cleveland Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012
Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery

Condition: Ischemic Stroke
Interventions: Drug: Extended-Release Niacin; Drug: Extended-Release Niacin; Drug: Placebo
Sponsors: Henry Ford Health System; Henry Ford Health System
Recruiting - verified July 2011
Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery

Conditions: Acute Kidney Injury; Post-Operative Delirium; Icu Delirium; Acute Renal Failure; Delirium
Interventions: Drug: atorvastatin; Drug: placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified July 2011
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified January 2012
Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)

Condition: HDL Cholesterol
Interventions: Drug: Simvastatin; Drug: Atorvastatin 80 mg
Sponsors: Oregon Health and Science University; Oregon Health and Science University; Merck; Oregon State University; Indiana University
Recruiting - verified August 2008
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial

Condition: Subarachnoid Haemorrhage
Interventions: Drug: placebo; Drug: simvastatin
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; British Heart Foundation
Recruiting - verified June 2011
Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Lovastatin; Drug: Placebo
Sponsors: National Jewish Health; National Jewish Health; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011
A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred

Conditions: Hodgkin's Disease; Non-Hodgkin's Lymphoma
Interventions: Drug: Vorinostat (SAHA) and Niacinamide; Drug: Vorinostat, Niacinamide and Etoposide
Sponsors: Columbia University; Columbia University; Merck
Recruiting - verified February 2012
Evaluation of Lovastatin in Severe Persistent Asthma

Condition: Severe Persistent Asthma
Interventions: Drug: Lovastatin; Drug: Placebo
Sponsors: University of Chicago; University of Chicago
Not yet recruiting - verified August 2011
Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia

Conditions: HIV Infections; Hyperlipidemia
Intervention: Drug: Atorvastatin
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012
Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury

Condition: Prostate Cancer
Intervention: Drug: lovastatin
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; Hunter Holmes Mcguire Veteran Affairs Medical Center
Recruiting - verified April 2012
Statin Therapy Versus Placebo Prior to Prostatectomy

Conditions: Cancer; Prostate
Interventions: Drug: Simvastatin; Other: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Oregon Health and Science University
Recruiting - verified May 2012
The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol

Condition: Sitosterolemia
Intervention: Behavioral: High/Low Sitosterol
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2011
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation

Conditions: Metabolic Syndrome X; Prediabetic State
Interventions: Drug: Fenofibrate; Drug: Pioglitazone and Fenofibrate; Drug: Fenofibrate; Drug: Pioglitazone and Fenofibrate
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Lovastatin; Device: Lovastatin placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Autoimmunity Centers of Excellence
Recruiting - verified September 2011
Atorvastatin to Treat Pulmonary Sarcoidosis

Condition: Sarcoidosis, Pulmonary
Intervention: Drug: Atorvastatin
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011
Phase II Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma

Conditions: Leukemia; Lymphoma, Non-Hodgkin
Interventions: Drug: Atorvastatin; Procedure: CT scan of chest/abdomen/pelvis
Sponsors: Stanford University; Stanford University; The Leukemia and Lymphoma Society; Damon Runyon Cancer Research Foundation; Burroughs Wellcome
Recruiting - verified November 2011